Polen Capital Management
PACB icon

Polen Capital Management’s Pacific Biosciences PACB Stock Holding History

Polen Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,149
Closed -$256K – 270
2025
Q4 		$256K Buy
+137,149
New +$264K ﹤0.01% 217

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Polen Capital Management's PACB Position: Q1 2026 in Review

Polen Capital Management sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 137,149 shares — an estimated $256K sold.

Polen Capital Management first reported a position in PACB in Q4 2025 and held it in 1 quarter. The position peaked at $256K in Q4 2025. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Polen Capital Management reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Polen Capital Management sold 137,149 Pacific Biosciences shares in Q1 2026, an estimated $256K.
  • Polen Capital Management first reported a position in Pacific Biosciences in Q4 2025 and held it in 1 quarter.
  • Polen Capital Management's Pacific Biosciences position peaked at $256K in Q4 2025.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Polen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.